Evidence map›Paper›PMID 42010983›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2026

Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosis.

Karlo Toljan, Brian Renner, Lynn Daboul, Melissa L Martin, Quy Cao, Carly M O'Donnell, Paulo Rodrigues, John Derbyshire, Christina J Azevedo, Amit Bar-Or and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Karlo ToljanMellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-3189-9659
Brian RennerDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Lynn DaboulTranslational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA; Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Melissa L MartinDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Penn Statistics in Imaging and Visualization Endeavor, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Quy CaoDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Penn Statistics in Imaging and Visualization Endeavor, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-6204-1305
Carly M O'DonnellDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Penn Statistics in Imaging and Visualization Endeavor, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Paulo RodriguesQMENTA Inc., Boston, MA, USA.
John DerbyshireFunctional MRI Facility, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Christina J AzevedoDepartment of Neurology, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0002-8622-1845
Amit Bar-OrDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-7179-0335
Eduardo CaverzasiDepartment of Neurology, Weill Institute for Neurosciences, University of California at San Francisco, San Francisco, CA, USA; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; Neuroradiology Department, Advanced Imaging and Radiomics Center, IRCCS Mondino Foundation, Pavia, Italy.ORCID 0000-0002-0350-0460
Peter A CalabresiDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-7776-6472
Bruce A C CreeDepartment of Neurology, Weill Institute for Neurosciences, University of California at San Francisco, San Francisco, CA, USA.ORCID 0000-0001-7689-2533
Leorah FreemanDepartment of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.
Roland G HenryDepartment of Neurology, Weill Institute for Neurosciences, University of California at San Francisco, San Francisco, CA, USA.
Erin E LongbrakeDepartment of Neurology, Yale University, New Haven, CT, USA.
Kunio NakamuraDepartment of Biomedical Engineering, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-7833-8138
Jiwon OhDivision of Neurology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-5519-6088
Nico PapinuttoDepartment of Neurology, Weill Institute for Neurosciences, University of California at San Francisco, San Francisco, CA, USA.
Daniel PelletierDepartment of Neurology, University of Southern California, Los Angeles, CA, USA.
Rohini D SamudralwarDepartment of Neurology, University of Texas Health Science Center at Houston, Houston, TX, USA.
Matthew K SchindlerDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Elias S SotirchosDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-8812-1637
Nancy L SicotteDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Andrew J SolomonDepartment of Neurological Sciences, Larner College of Medicine, University of Vermont, Burlington, VT, USA.ORCID 0000-0003-1602-1554
Russell T ShinoharaDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Penn Statistics in Imaging and Visualization Endeavor, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Center for Biomedical Image Computing and Analytics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Daniel S ReichTranslational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-2628-4334
Pascal SatiDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-6763-0125
Daniel OntanedaMellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-2838-9148

Funding

Multimodal MRI in Multiple SclerosisZIANS003119 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI REICH, DANIEL · 2010 to 2025
$53.4M
Harmonization of Multi-Site Neuroimaging Data from Complex Study DesignsR01MH123550 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI SHINOHARA, RUSSELL TAKESHI · 2020 to 2025
$4.0M
Advanced Statistical Analytics of MRI in MSR01NS112274 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI SHINOHARA, RUSSELL TAKESHI · 2020 to 2024
$2.8M
Interactions between Gut Microbiome and B-Cell Depletion in Multiple SclerosisK23NS107624 · NINDS · YALE UNIVERSITY · PI LONGBRAKE, ERIN · 2019 to 2023
$980k
Intramural NIH HHS ZIA NS003119NIMH NIH HHS R01 MH123550NINDS NIH HHS K23 NS107624NINDS NIH HHS R01 NS112274
6 · The paper itself

Abstract

backgroundThe central vein sign (CVS) and the paramagnetic rim lesion (PRL) are neuroimaging biomarkers of multiple sclerosis (MS).

objectivesTo determine the diagnostic performance of CVS and PRL integration in people presenting for initial diagnostic evaluation of MS.

methodsAdults with clinical/radiological suspicion of MS, aged 18-65, with CVS and PRL assessment from the CentrAl Vein Sign in MS (CAVS-MS) pilot were included. Diagnostic performance of CVS and PRL combinations was evaluated, with 2017 McDonald criteria as the reference standard.

resultsSeventy-eight participants were included (71% female, 86% white, 37 with MS). The combination of ⩾1 CVS and ⩾1 PRL demonstrated sensitivity/specificity of 0.76 (95% CI, 0.59, 0.88) and 0.93 (95% CI, 0.80, 0.98). The combination of ⩾6 CVS and ⩾1 PRL demonstrated sensitivity/specificity of 0.57 (95% CI, 0.39, 0.73) and 1.00 (95% CI, 0.91, 1.00). In those with cerebrospinal fluid testing ( DISCUSSION: Integrating CVS and PRL represents potentially advantageous MS diagnostic biomarkers, with increased specificity and without substantial reduction in sensitivity.

Indexed as

Magnetic Resonance ImagingMultiple SclerosisNeuroimagingAdolescentAdultAgedFemaleHumansMaleMiddle AgedPilot ProjectsSensitivity and SpecificityYoung AdultBiomarkercentral vein signdiagnostic imagingmultiple sclerosisparamagnetic rim lesion

Identifiers

PMID42010983
PMCPMC13138446

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.